Navigation Links
Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database

ry mouth that is approved in the U.S. as a prescription medical device. QUADRAMET(R) (samarium Sm-153 lexidronam injection) is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT(R) (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer and SOLTAMOX(TM) (tamoxifen citrate) is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy centers on attaining sustainable growth through clinical, commercial, and strategic initiatives.

A copy of the full prescribing information for CAPHOSOL, QUADRAMET, PROSTASCINT and SOLTAMOX, including Boxed Warnings, warnings, precautions, adverse events and other safety information may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at http://www.cytogen.com. The Company's website is not part of this press release.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen's results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen's business is subject to a n
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
3. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, 2015 ... OFF HOLD -- FN Media Group LLC, PIV757417 ... Partnerships Focus on Developing Orphan Drug Products & ... is now OFF HOLD. Distribution time: 3 Aug ... development agreements between biotech companies, military surgical research ...
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
(Date:8/3/2015)... , ... August 03, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today welcomed the ... for review OPKO’s New Drug Application for a new treatment for chronic kidney ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 13 article from The Daily Mail titled ... Natural Painkiller That Can Last 'For Five Weeks'" discusses the use of stem ... study showed that harvesting stem cell-rich bone marrow from the hip, known as bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... today that Joe Williams has joined its growing California employee benefits division. ... service model to his clients. Mr. Williams will be joining the newly integrated ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... A new study has dismissed any association between consumption of ... association between total calcium intake//, and consequent changes in body ... intake of calcium. ,More than 19,000 men between ... a 12-year period. All of the study participants consumed a ...
... health benefits. Now, teens, who want that dream weight, can ... obesity at bay, according to a new study. Researchers at ... combined yoga with breathing exercises certainly helped knock off the ... boys participated in a study. They were divided into two ...
... appear to have scaled up following the improvement in ... flu outbreak abated.// , ,According to an official ... been some improvement in the movement of these commodities ... in the last four days. Poultry consumption too has ...
... Information (CIHI) said that despite the government investing a ... of waiting time. // Glenda Yeates, president of the ... and high-priority procedures has increased dramatically. ,But ... much. Statistics show that the number of angioplasties and ...
... study claims that calcium intake was not associated with weight ... published in the American Journal of Clinical Nutrition. ... enrolled in the Health Professionals Follow-up Study were taken as ... between total calcium intake from diet and supplements and changes ...
... eastern Sarawak state of Malaysia is causing concern among Malaysian ... all schools in the area to prevent the disease from ... causes the disease, has so far affected more than a ... peninsular Malaysia, the health ministry will take a clear line ...
Cached Medicine News:
... The ESR-100 is an automated 100-position ESR ... 50 samples daily. The instrument accurately and ... in 1.2ml or 2.0ml ESR-Vacuum Tubes. Results ... Westergren Method) and are available in 30 ...
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
... Qwik-Let® Premier is our top-of-the-line ... the attributes of the Qwik-Let® ... patented Lan-X feature. The Lan-X ... and protection in the removal ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
Medicine Products: